drugset / Trial / NCT00701311

An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

NCT00701311

Phase 2 Completed 21 enrolled Kenneth Peters, MD Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

Prostatitis is the most common urologic diagnosis in men under the age of 50 and the third most common diagnosis in older men. In Chronic Prostatitis (CP) or Chronic Pelvic Pain Syndrome (CPPS), men have lower urinary tract symptoms, pelvic pain, sexual dysfunction and decreased quality of life. Little is known about the cause of CP/CPPS. Likewise, no definitive therapy exists for CP/CPPS. We plan to study the use of CC-10004 in men with CP/CPPS.

Timeline

Start
2008-06
Primary completion
2011-01
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 20 mg Oral

Indications